This update is written for patients, carers and non-specialists. It is not medical advice, but it may help explain why specialist assessment, careful monitoring and joined-up care are so important in aspergillosis.
Key points
- Aspergillosis is not one single illness. It includes allergic, chronic and invasive forms, each needing different assessment and treatment.
- Several recent papers show that Aspergillus disease often develops where the lungs are already vulnerable, damaged or scarred.
- Invasive aspergillosis remains mainly a concern for people who are severely unwell or immunocompromised.
- Antifungal resistance, drug interactions and access to specialist fungal diagnostics continue to be important themes.
- Some papers describe unusual or experimental approaches, but these should not be seen as standard treatment unless recommended by a specialist team.
1. Aspergillosis can develop in already damaged lungs
One recent case report described chronic pulmonary aspergillosis complicated by a bacterial lung abscess inside a lung cavity. The patient was successfully treated with percutaneous drainage, where fluid or infected material is drained through the skin using imaging guidance, alongside medical care.
Another recent paper examined aspergillosis complicating idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis is a serious lung-scarring condition. This paper is important because fungal infection in people with fibrotic lung disease remains relatively understudied.
A separate review on the gut-lung axis in people with cystic fibrosis on CFTR modulators also reflects the growing interest in how long-term lung disease, airway microbes, inflammation and wider body systems interact. This is not only about Aspergillus, but it is relevant to understanding why airway infections and immune responses can vary between patients.
Why this matters: Aspergillus can sometimes take advantage of areas of lung that are already damaged by previous infection, cavities, scarring, bronchiectasis, chronic obstructive pulmonary disease, tuberculosis, cystic fibrosis, fibrosis or other long-term lung conditions. This does not mean everyone with lung damage will develop aspergillosis, but it does explain why doctors may investigate new or worsening symptoms carefully.
2. Nutritional health and immune resilience
A paper on aspergillosis in anorexia nervosa reported two cases and reviewed previous published cases. Severe malnutrition can affect the immune system, making some infections more likely or harder to recover from.
Why this matters: nutrition is part of immune resilience. This does not mean that poor diet directly causes aspergillosis, but severe undernutrition may reduce the body’s ability to respond to infection. For patients living with chronic illness, maintaining nutrition, weight and muscle strength can be an important part of overall care.
3. Invasive aspergillosis remains a serious infection in high-risk groups
Several papers this week focused on invasive aspergillosis. These included a 12-year retrospective cohort study of invasive aspergillosis in children, a review of invasive mould infections in children, and a case report of pulmonary aspergillosis following severe fever with thrombocytopenia syndrome.
Other papers reported invasive Aspergillus disease in very specific high-risk settings, including extensive facial tissue necrosis after paediatric peripheral blood stem cell transplantation and a Chinese-language report on bronchoscopic interventional therapy for invasive pulmonary aspergillosis.
Why this matters: invasive aspergillosis is different from allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis. It usually occurs in people who are severely unwell or whose immune system is significantly weakened. It is a medical emergency and requires urgent specialist care.
For patients and families, it is useful to understand that the word aspergillosis covers several different diseases. The outlook, urgency and treatment plan can be very different depending on which form is present.
4. Better diagnosis depends on awareness and laboratory capacity
A French multicentre survey looked at laboratory capacity for diagnosing fungal infections. This type of research is important because diagnosis does not depend only on the doctor thinking of fungal disease. It also depends on access to the right laboratory tests, fungal culture, antigen testing, molecular testing, susceptibility testing and specialist interpretation.
Another paper on primary ciliary dyskinesia in children included aspergillosis among the infections and differential diagnoses clinicians may need to consider when assessing complex chronic respiratory symptoms. Although this was not primarily an aspergillosis paper, it reinforces the wider point that fungal disease can be part of a broader diagnostic picture in patients with long-term airway problems.
Why this matters: delays in diagnosing aspergillosis are common. Improving diagnosis means improving the whole pathway: clinical awareness, access to tests, expert laboratories and specialist teams who can interpret complex results.
5. Antifungal resistance remains an important issue
A review on a One Health approach to antifungal resistance in allergic bronchopulmonary aspergillosis highlighted the wider problem of antifungal resistance. A One Health approach recognises that human health, animal health and the environment are connected.
Aspergillus species live widely in the environment. Resistance may emerge not only through medical antifungal use, but also through environmental exposure to antifungal compounds used in agriculture or other settings.
Why this matters: antifungal resistance can make treatment more difficult. This is one reason why specialist teams may request fungal cultures, susceptibility testing, antifungal drug-level monitoring or treatment changes. It is also why antifungals should be used carefully and monitored properly.
6. Drug interactions are a practical safety issue
One paper examined possible drug interactions between midostaurin and posaconazole in people with a type of acute myeloid leukaemia. Although this is a specialist cancer-treatment paper, it illustrates a wider issue that is relevant to many patients taking antifungal medicines.
Azole antifungals such as itraconazole, voriconazole, posaconazole and isavuconazole can interact with other medicines. These interactions may affect antifungal levels, side effects or the levels of other medicines.
Why this matters: patients taking antifungals should tell their doctor and pharmacist about all prescribed medicines, over-the-counter medicines, inhalers, herbal products and supplements. Monitoring is part of safe antifungal treatment.
7. New or alternative antifungal approaches are being explored
One case report described pulmonary aspergillosis treated with oral amphotericin B, known as MAT2203, in a patient with human immunodeficiency virus-related cryptococcal meningitis. This is interesting because amphotericin B is usually given intravenously, and oral formulations are being explored for specific situations.
A Scite literature check also highlighted recent specialist papers on endoscopic liposomal amphotericin B therapy in semi-invasive pulmonary aspergillosis and newer antifungal approaches such as manogepix. These were not central to the PubMed list used for this update, but they support the wider message that antifungal research is active.
Why this matters: research into new ways of treating Aspergillus infection is active. This is encouraging, especially for difficult cases where standard antifungal treatment is limited by resistance, side effects or interactions. However, case reports and early-stage studies should not be seen as proof that a treatment is ready for routine use.
8. Allergic bronchopulmonary aspergillosis guidance continues to evolve
A Chinese-language expert consensus paper considered the diagnosis and treatment of allergic bronchopulmonary aspergillosis with integrated traditional Chinese and western medicine. This is not directly applicable to UK practice, but it reflects the continued international interest in improving diagnosis and management of allergic bronchopulmonary aspergillosis.
Why this matters: allergic bronchopulmonary aspergillosis can be difficult to diagnose because it overlaps with asthma, bronchiectasis, mucus plugging, raised immunoglobulin E and eosinophilic inflammation. Different countries and specialist groups continue to refine how they classify and manage the condition.
9. Laboratory science continues to improve understanding of Aspergillus
One paper investigated Aspergillus fumigatus morphogenesis and pathogenesis through a putative lipid transporter called ArvA. This is laboratory-based science rather than an immediate patient-care paper.
Why this matters: basic science helps researchers understand how Aspergillus grows, adapts and interacts with the immune system. Over time, this type of work may help identify new treatment targets or explain why some infections behave differently from others.
10. A note of caution about non-standard treatments
One paper reported follow-up of a previous aspergillosis case treated with oxygen-ozone therapy. This should be interpreted very cautiously. Pulmonary aspergillosis usually requires specialist assessment and, when treatment is needed, evidence-based antifungal therapy and monitoring.
Important: patients should not stop prescribed antifungal treatment or replace it with non-standard approaches without discussion with their specialist clinical team.
What this means for patients
This week’s research shows again that aspergillosis is complex. It can be allergic, chronic or invasive. It can affect people with asthma, cystic fibrosis, damaged lungs, weakened immune systems or severe underlying illness. It may require imaging, blood tests, sputum tests, bronchoscopy, antifungal drug monitoring and careful review by experienced clinicians.
The most useful message for patients is that persistent or worsening symptoms should be taken seriously, especially in people with known lung disease or immune problems. Good communication with healthcare teams, careful monitoring and specialist fungal expertise remain central to safe care.
When to seek medical advice
People living with aspergillosis or long-term lung disease should seek medical advice if they notice:
- new or worsening breathlessness
- coughing up blood
- persistent fever or night sweats
- unexplained weight loss
- worsening fatigue or weakness
- new chest pain
- symptoms that are not improving despite treatment
- possible side effects from antifungal medicines
Urgent medical help is needed for severe breathlessness, significant coughing up of blood, confusion, collapse, severe chest pain or rapidly worsening symptoms.
References and papers included in this update
- Okazaki Y, Shirata M, Koma K, et al. Chronic pulmonary aspergillosis complicated by a lung abscess within a pulmonary cavity successfully treated with percutaneous drainage: A case report.
Internal Medicine. 2026. - Mercier A, Loridant S, Tetart M, et al. Aspergillosis in anorexia nervosa: a report of two cases and review of the literature.
BMC Infectious Diseases. 2026. - Gutierrez-Perez C, Jones JT, Puerner CTS, et al. Insights into Aspergillus fumigatus morphogenesis and pathogenesis through the putative lipid transporter ArvA.
mSphere. 2026. - Greydanus DE, Bhave SY, Ashok N, Goel A. Primary ciliary dyskinesia in pediatric persons: A microscopic movement malady.
Disease-a-Month. 2026. - Lai X, Gao Q, Wu L. A 56-Year-Old Male Farmer From China With Severe Fever With Thrombocytopenia Syndrome and Pulmonary Aspergillosis: A Case Report and Review of Literature.
American Journal of Case Reports. 2026. - Morio F, Alanio A, Boukris-Sitbon K, et al. Assessing Laboratory Capacity for Diagnosis of Fungal Infections in France: A Multicentre survey within the SINFONI Network.
Medical Mycology. 2026. - Falcon RMG, Asedillo KFY, Gilo AJG, et al. One health approach to management of antifungal resistance in allergic bronchopulmonary aspergillosis.
Molecular Biology Reports. 2026. - Kagimu E, Senkoro E, Gakuru J, et al. Pulmonary Aspergillosis Treated With Oral Amphotericin B (MAT2203) in a Patient With HIV-Related Cryptococcal Meningitis.
Clinical Case Reports. 2026. - Lefranc M, Ramel E, Marsh R, et al. Towards a gut-lung axis role in pwCF on CFTR modulators: rationale, clinical evidence and perspectives.
Journal of Cystic Fibrosis. 2026. - Bermudez J, Debray MP, Uzunhan Y, et al. Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.
Respiratory Medicine. 2026. - Franzini M, Valdenassi L, Chirumbolo S. Follow up of a previous aspergillosis case report treated with oxygen-ozone therapy, reporting clinical remission of the lung fungal infection.
International Immunopharmacology. 2026. - Karaman A, Cengiz AB, Aykac K, et al. Evaluation of the Clinical Characteristics and Survival of Pediatric Patients with Invasive Aspergillosis: A 12-year Retrospective Cohort Study.
Mycopathologia. 2026. - Joisten CS, Mellinghoff SC, Seidel D, et al. Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.
Antimicrobial Agents and Chemotherapy. 2026. - Lim H, Kim MW, Lee JW. Delayed Anterolateral Thigh Free Flap Reconstruction for Extensive Buccal-Midfacial Necrosis Caused by Invasive Aspergillosis After Pediatric PBSCT: A 7-Year Follow-Up.
Journal of Craniofacial Surgery. 2026. - Warris A, Rojo P, Groll AH, Arrieta AC. Invasive mold infections in the pediatric setting: current status and new developments.
Expert Review of Anti-Infective Therapy. 2026. - Li J, Cai CL, Zhao LN, Wang YH, Mu XD. Clinical analysis of comprehensive bronchoscopic interventional therapy for invasive pulmonary aspergillosis.
Zhonghua Jie He He Hu Xi Za Zhi. 2026. - Allergy Committee of Chinese Association of Integrative Medicine. Expert consensus on the diagnosis and treatment of allergic bronchopulmonary aspergillosis with integrated traditional Chinese and western medicine: 2026 edition.
Zhonghua Yi Xue Za Zhi. 2026.
Editor’s note
This article is based mainly on a PubMed search for recent aspergillosis papers. Each reference links to its PubMed record where readers can view the abstract, journal details and, where available, links to free full text. A brief Scite search was also used to identify related recent papers and research themes, but the main patient-facing interpretation has been written from the PubMed results listed above.
Last reviewed: May 2026
Latest News posts
News archive